A detailed history of Deka Bank Deutsche Girozentrale transactions in Regenxbio Inc. stock. As of the latest transaction made, Deka Bank Deutsche Girozentrale holds 74,600 shares of RGNX stock, worth $740,032. This represents 0.0% of its overall portfolio holdings.

Number of Shares
74,600
Previous 74,600 -0.0%
Holding current value
$740,032
Previous $1.64 Million 47.45%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 24, 2024

BUY
$12.89 - $20.82 $476,930 - $770,340
37,000 Added 98.4%
74,600 $1.38 Million
Q1 2022

Apr 28, 2022

BUY
$24.62 - $34.31 $83,708 - $116,654
3,400 Added 9.94%
37,600 $1.24 Million
Q4 2021

Feb 02, 2022

BUY
$30.19 - $40.28 $27,171 - $36,252
900 Added 2.7%
34,200 $1.11 Million
Q3 2021

Oct 22, 2021

SELL
$29.09 - $45.68 $581,800 - $913,600
-20,000 Reduced 37.52%
33,300 $1.4 Million
Q4 2020

Mar 12, 2021

SELL
$26.52 - $49.35 $602,004 - $1.12 Million
-22,700 Reduced 29.87%
53,300 $2.47 Million
Q3 2020

Oct 29, 2020

BUY
$27.01 - $40.26 $2.05 Million - $3.06 Million
76,000 New
76,000 $2.09 Million
Q3 2019

Nov 14, 2019

SELL
$31.84 - $50.88 $216,512 - $345,984
-6,800 Closed
0 $0
Q2 2019

Aug 01, 2019

SELL
$42.0 - $59.29 $709,800 - $1 Million
-16,900 Reduced 71.31%
6,800 $338,000
Q1 2019

May 10, 2019

BUY
$40.82 - $62.45 $175,526 - $268,535
4,300 Added 22.16%
23,700 $1.74 Million
Q4 2018

Feb 12, 2019

SELL
$39.11 - $75.15 $168,173 - $323,145
-4,300 Reduced 18.14%
19,400 $804,000
Q3 2018

Nov 09, 2018

SELL
$65.0 - $82.15 $39,000 - $49,290
-600 Reduced 2.47%
23,700 $0
Q2 2018

Aug 14, 2018

BUY
$27.2 - $74.35 $326,400 - $892,199
12,000 Added 97.56%
24,300 $1.75 Million
Q1 2018

May 03, 2018

BUY
$24.05 - $37.5 $295,815 - $461,250
12,300 New
12,300 $361,000

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $429M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Deka Bank Deutsche Girozentrale Portfolio

Follow Deka Bank Deutsche Girozentrale and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.